Liquid biopsy: blood-based analyses of circulating cell-free DNA in xenografts

Isabel Heidrich; Klaus Pantel

doi:10.15252/emmm.202216326

Liquid biopsy: blood-based analyses of circulating cell-free DNA in xenografts

Standard

Liquid biopsy: blood-based analyses of circulating cell-free DNA in xenografts. / Heidrich, Isabel ; Pantel, Klaus.

in: EMBO MOL MED, Jahrgang 14, Nr. 8, e16326, 08.08.2022.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › Andere (Vorworte u.ä.) › Forschung

Harvard

Heidrich, I & Pantel, K 2022, 'Liquid biopsy: blood-based analyses of circulating cell-free DNA in xenografts', EMBO MOL MED, Jg. 14, Nr. 8, e16326. https://doi.org/10.15252/emmm.202216326

APA

Heidrich, I., & Pantel, K. (2022). Liquid biopsy: blood-based analyses of circulating cell-free DNA in xenografts. EMBO MOL MED, 14(8), [e16326]. https://doi.org/10.15252/emmm.202216326

Vancouver

Heidrich I , Pantel K. Liquid biopsy: blood-based analyses of circulating cell-free DNA in xenografts. EMBO MOL MED. 2022 Aug 8;14(8). e16326. https://doi.org/10.15252/emmm.202216326

Bibtex

@article{c8ae1d9f6f484318a0edf91da662cbc9,

title = "Liquid biopsy: blood-based analyses of circulating cell-free DNA in xenografts",

abstract = "The liquid biopsy concept has been introduced for circulating tumor cells more than 10 years ago (Pantel & Alix-Panabieres, 2010) and rapidly extended to cell-free DNA released from tumor cells (ctDNA; Lo et al, 2021) and other tumor-derived products such as circulating cell-free RNA (noncoding and messenger RNA), extracellular vesicles, or tumor-educated platelets (Alix-Panabi{\`e}res & Pantel, 2021). In this issue of EMBO Molecular Medicine, the report of Sauer et al (2022) demonstrates the feasibility of longitudinal monitoring of disease burden and response using ctDNA from dried blood spots in xenograft models.",

keywords = "Animals, Biomarkers, Tumor, Cell-Free Nucleic Acids, Circulating Tumor DNA/genetics, Heterografts, Humans, Liquid Biopsy, Neoplastic Cells, Circulating",

author = "Isabel Heidrich and Klaus Pantel",

note = "{\textcopyright} 2022 The Authors. Published under the terms of the CC BY 4.0 license.",

year = "2022",

month = aug,

day = "8",

doi = "10.15252/emmm.202216326",

language = "English",

volume = "14",

journal = "EMBO MOL MED",

issn = "1757-4676",

publisher = "Wiley-Blackwell",

number = "8",

}

RIS

TY - JOUR

T1 - Liquid biopsy: blood-based analyses of circulating cell-free DNA in xenografts

AU - Heidrich, Isabel

AU - Pantel, Klaus

PY - 2022/8/8

Y1 - 2022/8/8

N2 - The liquid biopsy concept has been introduced for circulating tumor cells more than 10 years ago (Pantel & Alix-Panabieres, 2010) and rapidly extended to cell-free DNA released from tumor cells (ctDNA; Lo et al, 2021) and other tumor-derived products such as circulating cell-free RNA (noncoding and messenger RNA), extracellular vesicles, or tumor-educated platelets (Alix-Panabières & Pantel, 2021). In this issue of EMBO Molecular Medicine, the report of Sauer et al (2022) demonstrates the feasibility of longitudinal monitoring of disease burden and response using ctDNA from dried blood spots in xenograft models.

AB - The liquid biopsy concept has been introduced for circulating tumor cells more than 10 years ago (Pantel & Alix-Panabieres, 2010) and rapidly extended to cell-free DNA released from tumor cells (ctDNA; Lo et al, 2021) and other tumor-derived products such as circulating cell-free RNA (noncoding and messenger RNA), extracellular vesicles, or tumor-educated platelets (Alix-Panabières & Pantel, 2021). In this issue of EMBO Molecular Medicine, the report of Sauer et al (2022) demonstrates the feasibility of longitudinal monitoring of disease burden and response using ctDNA from dried blood spots in xenograft models.

KW - Animals

KW - Biomarkers, Tumor

KW - Cell-Free Nucleic Acids

KW - Circulating Tumor DNA/genetics

KW - Heterografts

KW - Humans

KW - Liquid Biopsy

KW - Neoplastic Cells, Circulating

U2 - 10.15252/emmm.202216326

DO - 10.15252/emmm.202216326

M3 - Other (editorial matter etc.)

C2 - 35903952

VL - 14

JO - EMBO MOL MED

JF - EMBO MOL MED

SN - 1757-4676

IS - 8

M1 - e16326

ER -